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The expanding use of the epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor erlotinib in the manage-
ment of patients with advanced non-small cell lung cancer
has led to an interest in the early identification of those who
are likely to gain benefit. We present the case of a patient with
a durable clinical response, who developed trichomegaly (ex-
cessive eyelash growth) without the characteristic skin rash.
CASE REPORT
A 61-year-old female never-smoker presented with a
3-month history of increasing dyspnoea on exertion and
persistent cough. Chest radiogram and computed chest to-
mography (CT) showed patchy infiltrates in the right mid-
lower lobes, but bronchoscopy was normal, with no endo-
bronchial lesion seen and no malignant cells in the bronchial
wash. A transbronchoscopic biopsy was not performed. Re-
peat imaging 3 months later confirmed progressive air space
consolidation, and a CT-guided fine-needle aspirate showed
features in keeping with a well-differentiated mucin variant
of bronchoalveolar carcinoma.
The patient’s only significant medical history was hy-
pertension and hypercholesterolaemia, for which she had
been prescribed atorvastatin and propranolol.
This patient elected not to receive palliative platinum-
based combination chemotherapy; therefore, the potential of
erlotinib as initial therapy was discussed. Treatment com-
menced in April 2005, and erlotinib 150 mg daily was
prescribed through an expanded access program before li-
censing. Within 4 weeks, there was a marked symptomatic
improvement in exercise tolerance and almost complete res-
olution of the previous copious bronchial secretions. Radio-
logical imaging showed static disease (Figures 1 and 2). No
assessments for EGFR mutation status were performed in this
patient.
During the patient’s 10 months of treatment, she did not
develop any significant cutaneous or gastrointestinal toxicity,
which are commonly seen with this class of drug. After 3
months’ treatment, however, she did find it necessary to
“trim” her eyelashes, which were overgrowing and causing
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FIGURE 1. Chest computed tomographic scan before treat-
ment.
FIGURE 2. Chest computed tomographic scan after 3
months’ treatment with Erlotinib.
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visual disturbance and corneal irritation ( Figure 3). In addi-
tion to excessive growth, her eyelashes became dark and
coarse, whereas her scalp hair was fine and brittle.
DISCUSSION
Hypertrichosis of the eyelashes, known as tricho-
megaly, is seen in a number of congenital and acquired
conditions, such as HIV-1 infection, for which it has been
postulated as a clinical marker of disease severity. Tricho-
megaly is also associated with drugs such as phenytoin,
cyclosporin, diazoxide, minoxidil, streptomycin, penicilla-
mine, interferon 2, and latanoprost.
There have also been case reports of trichomegaly with
the EGFR inhibitors cetuximab and gefitinib.1,2
The cutaneous toxicity of the EGFR tyrosine kinase
inhibitors is seen as a class effect and commonly includes an
acneiform skin eruption, xerosis, paronychia, hyperpigmen-
tation, and telangiectasia, as well as hair changes—of which
trichomegaly is characteristic. EGFR expression and activa-
tion occurs in the basal epidermal cells, sebaceous glands,
and outer root sheath of hair follicles and is necessary to
stimulate the proliferation, differentiation, and survival of
keratinocytes.3
The pathogenesis of these symptoms is largely un-
known, but there is evidence that this is directly linked to
inhibition of the EGFR. Cutaneous effects develop regardless
of whether the inhibition is by a monoclonal antibody (cetux-
imab) or by a small molecule tyrosine kinase inhibitor (ge-
fitinib, erlotinib). Cutaneous effects, however, are not seen
with inhibition of other members of the EGFR family, such as
Her-2 blockade with trastuzumab. There is some evidence
that tumor response correlates with the presence of skin rash,
and there is also a probable relationship between dose and
severity of rash. This has led to increased interest in the use of
cutaneous toxicity as a potential clinical marker of response, and
the idea of “dose-to-rash” is ongoing in clinical trials.
As the use of the EGFR tyrosine kinase inhibitors
continues to expand in non-small cell lung cancer, so our
search to identify those most likely to derive clinical benefit
becomes more common. Several factors, such as female sex,
never smokers, adenocarcinomas (particularly bronchoalveo-
lar), and Asian origin, are established as positive predictive
markers for clinical benefit. Research into EGFR tyrosine
kinase binding domain mutations forms an important part of
ongoing clinical trials;4 however, there are no published
prospective data, with previous results confined to retrospec-
tive analysis from small numbers of patients for whom tissue
samples are available. At present, there is insufficient infor-
mation to suggest that EGFR inhibitors should be confined to
any patient group.
SUMMARY
A characteristic acneiform skin rash is proving to be a
useful clinical tool, and other less common cutaneous toxic-
ities, such as isolated trichomegaly, may be similarly useful.
REFERENCES
1. Siegel-Lakhai WS, Beijnen JH, Schellens JH. Current knowledge and
future directions of the selective epidermal growth factor receptor
inhibitors Erlotinib (Tarcvea®) and Gefitinib (Iressa®) Oncologist 2005;
10:579–589.
2. Bouche O, Brixi-Benmansour H, Bertin A, et al. Trichomegaly of the
eyelashes following treatment with Cetuximab. Ann Oncol 2005;16:
1711–1712.
3. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and manage-
ment of skin toxicity during therapy with epidermal growth factor
receptor inhibitor. Ann Oncol 2005;16;1425–33.
4. Dueland S, Sauer T, Lund-Johansen F, et al. Epidermal growth factor
receptor inhibition inducing trichomegaly. Acta Oncol 2003;42:345–
346.
FIGURE 3. Excessive eyelash
growth after 8 months of treat-
ment.
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